Related Experiment Video

Updated: Jul 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic viruses driven by tumor-specific promoters

Jayson Hardcastle1, Kazuhiko Kurozumi, E Antonio Chiocca

  • 1Dardinger Laboratory for Neuro-Oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University, Columbus, Ohio 43210, USA.

Current Cancer Drug Targets
|March 10, 2007
PubMed

Insights

Oncolytic viruses offer targeted cancer cell destruction. Enhancing tumor selectivity and potency through transcriptional targeting is crucial for realizing their full therapeutic potential.

Area of Science:

  • Oncolytic virotherapy
  • Cancer genetics
  • Molecular virology

Background:

  • Oncolytic viruses selectively infect and lyse tumor cells.
  • First-generation oncolytic viruses were attenuated for safety, limiting their therapeutic efficacy.
  • Clinical trials confirmed safety but highlighted the need for more potent and tumor-specific viruses.

Purpose of the Study:

  • To review strategies for developing oncolytic viruses with enhanced tumor selectivity and potency.
  • To explore the use of tumor-specific transcriptional targeting to control viral virulence.

Main Methods:

  • Review of scientific literature on oncolytic virus design and cancer genetics.
  • Analysis of strategies employing tumor-specific transcriptional control of viral gene expression.
  • Focus on methods to govern viral virulence based on neoplastic cellular events.

Main Results:

  • First-generation oncolytic viruses demonstrate safety but require improved efficacy.
  • Tumor-specific transcriptional targeting offers a promising approach to enhance selectivity.
  • Exploiting molecular/genetic changes in cancer enables tailored viral virulence.

Conclusions:

  • Developing more potent and tumor-specific oncolytic viruses is essential for advancing cancer therapy.
  • Transcriptional targeting strategies are key to creating oncolytic viruses with controlled virulence.
  • Future oncolytic virus design will leverage cancer-specific genetic and molecular alterations.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...